Get the Daily Brief
Latest Biotech News
FDA Rejects Disc Medicine’s Bitopertin—Biomarker Link Deemed Uncertain
The FDA has rejected Disc Medicine’s bitopertin, the agency saying uncertainties remain about the surrogate blood biomarker used to support efficacy. The decision, reported by STAT, halted the...
Moderna’s Flu Review Stalls... Regulatory Pushback Ripples Through Biotech
The FDA declined to review Moderna’s mRNA flu vaccine application, a move that has clouded the company’s cash‑flow guidance and reignited debate over regulatory expectations for next‑generation...
Exact Sciences Q4 Revenue Jumps 23% — Shareholders to Vote on $23B Abbott Deal
Exact Sciences reported a 23% year‑over‑year revenue increase for Q4 2025 and beat consensus on screening volumes, lifting momentum ahead of a special shareholders’ meeting to approve Abbott’s...
Bio‑Rad’s ddPCR Lift—Product Momentum Meets Technology Adoption
Bio‑Rad reported modest overall revenue growth driven in part by expansion of its droplet digital PCR (ddPCR) business and stronger consumables pull‑through, the company said on its Q4 call....
Ultragenyx Cuts 10% of Workforce as FDA Flags Gene‑Therapy Gaps
Ultragenyx announced a restructuring that will eliminate roughly 130 roles—about 10% of headcount—citing a push toward profitability in 2027 and recent regulatory setbacks. The company said its...
Lyell Launches First‑of‑Its‑Kind CAR‑T Trial—Direct Test vs Marketed Products
Lyell Immunopharma has initiated a head‑to‑head CAR‑T clinical trial that will test its experimental cell therapy directly against marketed CAR‑T products. The design aims to generate comparative...
Anterior Raises $40M—AI Platform to Slash Care‑Approval Times
Anterior closed a $40 million financing to scale an AI platform that automates administrative clinical workflows for health plans, the company said. The platform is designed to accelerate...
Australia Launches World‑First Pediatric mRNA Brain‑Cancer Trial
Australia has launched Paedneo‑Vax, the first multisite pediatric trial testing individualized mRNA vaccines for aggressive childhood brain tumors. Funded by Providence Therapeutics with public...
Vertex’s CRISPR Therapy Rebounds—Casgevy Sales Triple in Latest Quarter
Vertex reported a significant sales increase for Casgevy, its CRISPR‑based gene therapy developed with CRISPR Therapeutics, with quarterly sales more than tripling versus the prior quarter....
VCs Launch European Life Science Coalition: €24B to Mobilize Investment
A consortium of venture capital firms and research institutions has formed the European Life Science Coalition to boost private and public investment into Europe’s biotech sector. The...
FDA rejects Disc therapy — expedited voucher route falters
The FDA rejected Disc Medicine’s bitopertin application, marking a high-profile rebuke of a rare-disease submission that had been expedited under a new priority-review voucher program. STAT...
NIAID reshapes priorities: biodefense and pandemic preparedness deprioritized
Internal directives at NIAID instructed staff to remove the terms “biodefense” and “pandemic preparedness” from public materials as the institute refocuses funding toward basic immunology and...
BridgeBio’s oral FGFR3 matches Voxzogo on height — adds pill option
BridgeBio reported that infigratinib, an oral FGFR3 inhibitor, produced height gains comparable to Voxzogo in trials for achondroplasia while offering an oral dosing option. BioCentury’s reporting...
Lyell launches head-to-head CAR-T trial: experimental therapy to face rivals
Lyell Immunopharma initiated a first-of-its-kind clinical trial testing its experimental CAR-T therapy directly against marketed CAR-T products, the company said. The trial will evaluate...
Quantx closes $85M Series B to advance oral immunology pipeline
Quantx Biosciences completed an $85 million Series B round to advance two oral immunology candidates toward the clinic: a STAT6 inhibitor and an IL-17 inhibitor. The company said the financing...
Australia launches world‑first pediatric mRNA brain‑cancer vaccine trial
Australia initiated Paedneo‑Vax, the first multisite pediatric trial testing individualized mRNA vaccines for children with aggressive brain tumors, funded by Providence Therapeutics and...
All of Us hits 1M participants — national diverse cohort complete
The NIH’s All of Us research program reached its recruitment goal of one million participants, delivering a cohort designed to reflect the diversity of the U.S. population. NIH reported the...
10x braces for modest growth — imaging‑free spatial tools advance
10x Genomics projected up to 4% revenue growth for 2026 and warned that constrained capital spending among customers will continue to pressure instrument revenue, while consumables demand —...
FDA declines to review Moderna flu shot — regulatory uncertainty ripples
The FDA declined to accept Moderna’s mRNA influenza vaccine for review, creating fresh regulatory uncertainty for mRNA platforms beyond COVID‑19 and prompting industry concern about shifting...
Gilead buys Genhouse cancer drug: $80M upfront for global rights
Gilead agreed to acquire global rights to an oral oncology candidate from China‑based Genhouse Bio for $80 million up front, a deal announced as Genhouse pursues a Hong Kong IPO. The transaction...